Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes

View ORCID ProfileMichael Hecker, Brit Fitzner, Kathrin Jäger, Jan Bühring, Margit Schwartz, Alexander Hartmann, Michael Walter, Uwe Klaus Zettl
doi: https://doi.org/10.1101/2020.11.17.20232975
Michael Hecker
1Rostock University Medical Center, Department of Neurology, Division of Neuroimmunology, Gehlsheimer Str. 20, 18147 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Hecker
  • For correspondence: michael.hecker@rocketmail.com michael.walter@med.uni-rostock.de
Brit Fitzner
1Rostock University Medical Center, Department of Neurology, Division of Neuroimmunology, Gehlsheimer Str. 20, 18147 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin Jäger
2Rostock University Medical Center, Institute for Clinical Chemistry and Laboratory Medicine, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
3Charité – Universitätsmedizin Berlin, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Augustenburger Platz 1, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Bühring
1Rostock University Medical Center, Department of Neurology, Division of Neuroimmunology, Gehlsheimer Str. 20, 18147 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margit Schwartz
1Rostock University Medical Center, Department of Neurology, Division of Neuroimmunology, Gehlsheimer Str. 20, 18147 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Hartmann
2Rostock University Medical Center, Institute for Clinical Chemistry and Laboratory Medicine, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Walter
2Rostock University Medical Center, Institute for Clinical Chemistry and Laboratory Medicine, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.hecker@rocketmail.com michael.walter@med.uni-rostock.de
Uwe Klaus Zettl
1Rostock University Medical Center, Department of Neurology, Division of Neuroimmunology, Gehlsheimer Str. 20, 18147 Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Aging is a significant factor influencing the course of multiple sclerosis (MS). Accelerated telomere attrition is an indicator of premature biological aging and a potential contributor to various chronic diseases, including neurological disorders. However, there is currently a lack of studies focusing on telomere lengths in patients with MS.

We measured the average leukocyte telomere length (LTL) in biobanked DNA samples of 40 relapsing-remitting MS patients (RRMS), 20 primary progressive MS patients (PPMS) and 60 healthy controls using a multiplex quantitative polymerase chain reaction method. Changes in LTL over a period of >10 years were evaluated in a subset of 10 patients. Association analyses of baseline LTL with the long-term clinical profiles of the patients were performed using inferential statistical tests and regression models adjusted for age and sex.

The cross-sectional analysis revealed that the RRMS group was characterized by a significantly shorter relative LTL, on average, as compared to the PPMS group and controls. Shorter telomeres at baseline were also associated with a higher conversion rate from RRMS to secondary progressive MS (SPMS) in the 10-year follow-up. The LTL decrease over time was similar in RRMS patients and PPMS patients in the longitudinal analysis.

Our data suggest a possible contributory role of accelerated telomere shortening in the pathobiology of MS. The interplay between disease-related immune system alterations, immunosenescence and telomere dynamics deserves further investigation. New insights into the mechanisms of disease might be obtained, e.g., by exploring the distribution of telomere lengths in specific blood cell populations.

Evidence before this study There is a growing research interest in the relationship between age and the pathophysiology and clinical presentation of multiple sclerosis (MS). Telomere shortening is a hallmark of biological aging. However, the role of telomeres in this chronic immune-mediated neurodegenerative disease has not yet been widely studied. Two research groups provided evidence that the telomeres of immune cells in the peripheral blood are shorter in patients with MS than in healthy subjects.

Added value of this study We found that leukocytes from patients with relapsing-remitting MS (RRMS) are characterized by relatively short telomere lengths (TL). On average, we observed 18% shorter TL in the RRMS patient cohort (n=40) than in the age- and sex-matched healthy control cohort (n=60). We further analyzed the association of TL and long-term clinical outcomes. RRMS patients with shorter TL had a higher rate of converting to secondary progressive MS over a 10-year follow-up period.

Implications of all the available evidence As we and others have shown, TL are generally shorter in MS patients and associated with disease progression, independent of age. These findings suggest a link between biological aging and the heterogeneous clinical course of MS patients. It currently remains unclear whether shortened telomeres in MS are a cause or a consequence of the pathophysiological processes. Further studies with larger patient cohorts and different cell populations will be needed to expand our knowledge of age-related disease mechanisms and the use of TL as a biomarker in MS.

Competing Interest Statement

MH received speaking fees and travel funds from Bayer HealthCare, Biogen, Merck, Novartis and Teva. UKZ received research support as well as speaking fees and travel funds from Almirall, Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi Genzyme and Teva. BF, KJ, JB, MS, AH and MW declare that they have no competing interests.

Funding Statement

This study was not funded.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the University of Rostock's ethics committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data of this study are provided in Supplemental Table 1.

  • Abbreviations

    ANOVA
    analysis of variance
    ARMSS
    Age-Related Multiple Sclerosis Severity
    BMI
    body mass index
    CI
    confidence interval
    CIS
    clinically isolated syndrome
    CNS
    central nervous system
    DDR
    DNA damage response
    DMT
    disease-modifying treatment
    EBV
    Epstein-Barr virus
    EDSS
    Expanded Disability Status Scale
    HHV
    human herpesvirus
    HR
    hazard ratio
    im
    intramuscular
    LTL
    leukocyte telomere length
    MS
    multiple sclerosis
    N
    number
    NA
    not applicable
    OR
    odds ratio
    PBMC
    peripheral blood mononuclear cells
    PCR
    polymerase chain reaction
    PPMS
    primary progressive multiple sclerosis
    RRMS
    relapsing-remitting multiple sclerosis
    S
    single-copy gene signal
    sc
    subcutaneous
    SD
    standard deviation
    SPMS
    secondary progressive multiple sclerosis
    T
    telomere signal
    TERC
    telomerase RNA component
    TERT
    telomerase reverse transcriptase
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted November 18, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes
    Michael Hecker, Brit Fitzner, Kathrin Jäger, Jan Bühring, Margit Schwartz, Alexander Hartmann, Michael Walter, Uwe Klaus Zettl
    medRxiv 2020.11.17.20232975; doi: https://doi.org/10.1101/2020.11.17.20232975
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes
    Michael Hecker, Brit Fitzner, Kathrin Jäger, Jan Bühring, Margit Schwartz, Alexander Hartmann, Michael Walter, Uwe Klaus Zettl
    medRxiv 2020.11.17.20232975; doi: https://doi.org/10.1101/2020.11.17.20232975

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Neurology
    Subject Areas
    All Articles
    • Addiction Medicine (62)
    • Allergy and Immunology (142)
    • Anesthesia (44)
    • Cardiovascular Medicine (408)
    • Dentistry and Oral Medicine (67)
    • Dermatology (47)
    • Emergency Medicine (141)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
    • Epidemiology (4810)
    • Forensic Medicine (3)
    • Gastroenterology (177)
    • Genetic and Genomic Medicine (671)
    • Geriatric Medicine (70)
    • Health Economics (187)
    • Health Informatics (621)
    • Health Policy (314)
    • Health Systems and Quality Improvement (200)
    • Hematology (85)
    • HIV/AIDS (155)
    • Infectious Diseases (except HIV/AIDS) (5280)
    • Intensive Care and Critical Care Medicine (326)
    • Medical Education (91)
    • Medical Ethics (24)
    • Nephrology (73)
    • Neurology (677)
    • Nursing (41)
    • Nutrition (110)
    • Obstetrics and Gynecology (124)
    • Occupational and Environmental Health (203)
    • Oncology (438)
    • Ophthalmology (138)
    • Orthopedics (36)
    • Otolaryngology (88)
    • Pain Medicine (35)
    • Palliative Medicine (15)
    • Pathology (127)
    • Pediatrics (193)
    • Pharmacology and Therapeutics (129)
    • Primary Care Research (84)
    • Psychiatry and Clinical Psychology (768)
    • Public and Global Health (1798)
    • Radiology and Imaging (321)
    • Rehabilitation Medicine and Physical Therapy (138)
    • Respiratory Medicine (255)
    • Rheumatology (86)
    • Sexual and Reproductive Health (68)
    • Sports Medicine (61)
    • Surgery (100)
    • Toxicology (23)
    • Transplantation (28)
    • Urology (37)